The findings come from the follow-up of the more than 46,000 volunteers who participated in phase 3 of the company’s clinical trials vaccine. Among them, 927 cases of covid-19 were registered until March 13, indicating an efficacy of 91.3%, calculated for the period between seven days and up to six months after the second dose: 850 were from the group that received a placebo and 77 received the vaccine.
According to the new analysis, the vaccine was 95.3% effective in protecting against the occurrence of severe disease, as defined by the United States’ drug regulatory agency, the FDA. From the evaluated group, more than 12 thousand participants have been followed for at least six months after the second dose, reinforcing the safety profile of the immunizer.
“It is an important step in confirming the high effectiveness and good safety data so far, especially in the long-term follow-up,” said the chief executive of BioNTech Germany, Ugur Sahin, in the note.
The study also showed that the vaccine appears to work in a similar way against the variant of the virus detected in South Africa, where this strain is a major strain and where it was 100% effective, albeit in a smaller group, with only 800 participants.
“The high effectiveness of the vaccine seen for up to six months after a second dose and against the variant prevalent in South Africa offers more confidence in the overall effectiveness of our vaccine,” said Pfizer CEO Albert Bourla.
The vaccine was the first licensed in the West and is a key part of immunization campaigns that take place in much of the world. / WITH INTERNATIONAL AGENCIES
Get the latest news delivered to your inbox
Follow us on social media networks